By proceeding, you agree to our Terms of Use and Privacy Policy.
The COVID-19 pandemic has not only stimulated interest in new modalities research but also sparked a resurgence in formulation approaches among biopharmaceutical companies, leading to the development of a new wave of drug substances and therapeutics. Over the past year, intranasal delivery methods have shown clinical efficacy for novel therapeutics, revolutionizing traditional vaccine methods and paving the way for a new generation of chronic CNS drugs. Pioneers in this field, including Tiziana Life Sciences, SciSparc, Odyssey Health, SaNOtize, and Intravacc, have garnered attention with their intranasal formulations entering clinical trials.To bring together over 60 senior leaders from biopharma, the Novel Nasal Formulation & Delivery Summit will be held in San Diego in collaboration with Cipla, Impel Pharmaceuticals, Neurelis, and SaNOtize. The summit aims to share approaches for formulating a novel nasal drug product that goes beyond small molecules, overcome challenges in bioavailability and permeability, deepen understanding of biophysiology and biodistribution, widen the therapeutic window, and ensure device compatibility for filing and speed-to-market. Attendees will be able to leverage new and existing connections to accelerate the globalization and commercialization of nasal products, given that the nasal market is projected to reach $74 billion in the near future. This is a great opportunity to stay ahead of the curve and consider venturing into this field. The summit will take place in May.
Deepen your biophysiological and bio-distribution understanding to reduce adsorption rate and immune response.
Widen the therapeutic window with patient centricity for your pipeline progression through a unique route of administration & enhance patient adherence.
Expand your network. Share approaches to formulate a novel nasal drug product with stability beyond small molecules & cross-learning from inhalations.
Optimize your formulation & device design to achieve bioavailability, safety & efficacy through intranasal routes of administration.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Every day, Aptar creates “a-ha moments” for its customers and their consumers and patients by continually bringing innovations to market that convert non-dispensing packaging into breakthrough product-dispensing systems, including those that give peo
Proveris helps pharmaceutical companies developing orally inhaled and nasal drug products (OINDPs) reach the market sooner, saving significant time and money.Proveris believes that developing effective OINDP products requires in-depth knowled
Proveris helps pharmaceutical companies developing orally inhaled and nasal drug products (OINDPs) reach the market sooner, saving significant time and money.Proveris believes that developing effective OINDP products requires in-depth knowledge and expertise to understand and control the com
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.